News coverage about Achillion Pharmaceuticals (NASDAQ:ACHN) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.7270529729789 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Are Options Traders Betting on a Big Move in Achillion Pharmaceuticals (ACHN) Stock? (zacks.com)
- Wondrous Stocks: Achillion Pharmaceuticals, Inc., (NASDAQ: ACHN), Square, Inc., (NYSE: SQ) – Global Export Lines (press release) (globalexportlines.com)
- The Stock on Analysts Watch-List: Achillion Pharmaceuticals, Inc. (ACHN) – Wall Street Morning (wallstreetmorning.com)
- Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2018 – Slideshow (seekingalpha.com)
Several brokerages recently commented on ACHN. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 27th. B. Riley began coverage on shares of Achillion Pharmaceuticals in a research report on Thursday, February 8th. They issued a “neutral” rating and a $3.50 price target for the company. Finally, Leerink Swann restated a “buy” rating and issued a $5.00 price target on shares of Achillion Pharmaceuticals in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company’s stock. Achillion Pharmaceuticals has an average rating of “Hold” and a consensus target price of $4.89.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same period in the prior year, the firm posted ($0.03) EPS. research analysts predict that Achillion Pharmaceuticals will post -0.55 EPS for the current fiscal year.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.